Vetr upgraded shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) from a strong sell rating to a sell rating in a report published on Wednesday morning. They currently have $107.00 target price on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the company. Piper Jaffray Cos. restated an overweight rating and issued a $185.00 price target on shares of Alexion Pharmaceuticals in a research report on Tuesday, August 16th. Morgan Stanley restated an overweight rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 29th. Brean Capital initiated coverage on Alexion Pharmaceuticals in a research report on Tuesday, October 4th. They issued a buy rating and a $221.00 price target for the company. Royal Bank Of Canada started coverage on Alexion Pharmaceuticals in a research note on Tuesday, July 12th. They issued an outperform rating and a $188.00 target price on the stock. Finally, Citigroup Inc. upgraded Alexion Pharmaceuticals from a neutral rating to a buy rating and set a $154.00 price target on the stock in a research note on Monday, June 27th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $178.32.

Analyst Recommendations for Alexion Pharmaceuticals (NASDAQ:ALXN)

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 118.17 on Wednesday. Alexion Pharmaceuticals has a 52 week low of $110.56 and a 52 week high of $193.45. The firm has a 50-day moving average of $126.61 and a 200 day moving average of $134.61. The firm has a market capitalization of $26.50 billion, a price-to-earnings ratio of 296.91 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The company earned $753 million during the quarter, compared to the consensus estimate of $743.18 million. Alexion Pharmaceuticals had a return on equity of 10.02% and a net margin of 3.19%. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.44 earnings per share. On average, equities analysts predict that Alexion Pharmaceuticals will post $4.67 earnings per share for the current fiscal year.

In other news, EVP Carsten Thiel sold 3,225 shares of the stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total value of $414,960.75. Following the transaction, the executive vice president now owns 40,354 shares in the company, valued at approximately $5,192,349.18. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Heidi L. Wagner sold 222 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $30,445.08. Following the completion of the transaction, the senior vice president now owns 32,115 shares in the company, valued at approximately $4,404,251.10. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new position in Alexion Pharmaceuticals during the first quarter worth approximately $114,000. NEXT Financial Group Inc increased its position in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Bellwether Investment Group LLC purchased a new position in Alexion Pharmaceuticals during the second quarter worth about $172,000. Charlemagne Capital Ltd. purchased a new position in Alexion Pharmaceuticals during the second quarter worth about $191,000. Finally, Atalanta Sosnoff Capital LLC purchased a new position in Alexion Pharmaceuticals during the third quarter worth about $206,000. Institutional investors and hedge funds own 96.34% of the company’s stock.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.